Abstract 1164P
Background
The standard approach for managing locally advanced rectal cancer includes preoperative neoadjuvant chemoradiotherapy followed by curative surgery, a regimen acknowledged for substantially enhancing local control rates. Nevertheless, the benefits of perioperative radiotherapy in treating rectal neuroendocrine carcinoma merit further investigation. This study explores the impact of preoperative neoadjuvant radiotherapy on the feasibility of sphincter-preserving surgery and on the overall survival rates in patients with locally advanced rectal neuroendocrine carcinoma.
Methods
Data from patients diagnosed with locally advanced (T3/T4 or N+) neuroendocrine carcinoma who underwent curative surgery from 2004 to 2019 were collected using the SEER database. We assessed clinical characteristics, treatment information, and overall survival rates. Statistical comparisons of categorical variables were performed using the Chi-square test or Fisher's exact test. Survival outcomes were analyzed using the Kaplan-Meier method.
Results
Of the 44 patients identified, 14 underwent preoperative neoadjuvant radiotherapy. Patients with a T-stage above T3 (42.9% vs. 12.5%, P = 0.049) and those without lymph node metastasis (87.5% vs. 19.4%, P < 0.001) were more likely to receive perioperative radiotherapy. The probability of performing sphincter-preserving surgery was notably lower in patients treated with neoadjuvant radiotherapy (57.1% vs. 93.3%, P = 0.008). Additionally, survival analysis indicated no significant relationship between neoadjuvant radiotherapy and overall survival (HR 1.298,95% CI:0.519-3. 244, P =0. 577).
Conclusions
Neoadjuvant radiotherapy prior to surgery did not improve the likelihood of performing sphincter-preserving procedures in patients with locally advanced rectal neuroendocrine carcinoma, nor did it significantly impact overall survival. Further research involving larger sample sizes is required to confirm these findings.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work, the author(s) used ChatGPT for editorial assistance in order to optimize content expression. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
W. Xu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
972P - Efficacy and safety of lenvatinib vs sorafenib in hepatocellular carcinoma: A multi-center real-world study from the LINK Research Network
Presenter: Jung Yong Hong
Session: Poster session 17
973P - Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 17
977P - Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: A multicenter cohort study
Presenter: Yi Chen
Session: Poster session 17
978P - Efficacy and safety analysis of transarterial chemoembolization combined donafenib with or without immune checkpoint inhibitors in for unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, single center, phase Ⅱ clinical study
Presenter: Jinpeng Li
Session: Poster session 17
979P - Initial results from the phase II randomized trial comparing TACE with irinotecan and mitomycin C to doxorubicin in intermediate stage HCC (IRITACE trial)
Presenter: Oliver Waidmann
Session: Poster session 17